Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: Identification of subgroups with low and high stage progression risks

Journal of Clinical Pathology

Volumn 56, Issue 6, 2003, Pages 447-452

  Bol, M G W ^a   Baak, J P A ^a   Van Diermen, B ^a   Buhr Wildhagen, S ^a   Janssen, E A M ^a   Kjellevold, K H ^a   Kruse, A J ^a   Mestad, O ^b   Ogreid P ^a  

^a SIR Hospital   (Norway)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ACCURACY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; FLOW CYTOMETRY; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE CYTOMETRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RISK FACTOR;

EID: 0038309593     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.6.447     Document Type: Article

References (32)

1. Lamm DL. Lang term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992;19:573-80.
2. Kiemeney LA, Witjes JA, Verbeek AL, et al. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 1993;67:806-12.
3. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer genitourinary tract cancer cooperative group and the Medical Research Council working party on superficial bladder cancer. J Urol 1996;156:1934-40.
4. Ooms ECM, Kurver PHJ, Veldhuizen RW, et al. Morphometric grading of bladder tumors in comparison with histologic grading by pathologists. Hum Pathol 1983;14:144-50.
5. Baak JPA. The case for quantitative pathology in cancer diagnosis and treatment. In: Manual of quantitative pathology in cancer diagnosis and prognosis. Berlin: Springer Verlag, 1991:7-18.
6. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of inter-observer differences in the staging and grading of superficial bladder cancer. BJU Int 2000;85:48-53.
7. Bol MGW, Baak JPA, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in Ta, T1 urothelial carcinomas of the urinary bladder. Urology 2002;60:1124-30.
8. Popov Z, Hoznek A, Colombel M, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80:1472-81.
9. Bol MGW, Baak JPA, Rep S, et al. Prognostic value of proliferative activity and nuclear morphometry for progression in urinary bladder Ta T1 urothelial cell carcinomas. Urology [In press.]
10. Pich A, Chiusa L, Comino A, et al. Cell proliferation indices, morphometry and DNA flow cytometry pravide abjective criteria for distinguishing low and high grade bladder carcinomas. Virchows Arch 1994;424:143-8.
11. Holmang S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumours: relationship to grade, immunohistochemical statement of tumour markers, mitotic frequency and DNA ploidy. J Urol 2001;165:1124-8.
12. Raitanen MP, Tammela TL, Kallioinen M, et al. P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol 1997;157:1250-3.
13. Masters JR, Camplejohn RS, Parkinson MC, et al. DNA ploidy and the prognosis of stage pT1 bladder cancer. Br J Urol 1989;64:403-8.
14. Schapers FR, Ploem-Zaaijer JJ, Pauwels RP, et al. Image cytometric DNA analysis in transitional cell carcinoma of the bladder. Cancer 1993;72:182-9.
15. Planz B, Synek C, Deix T, et al. Diagnosis of bladder cancer with urinary cytology, immunocytology and DNA-image-cytometry. Anal Cell Pathol 2001;22:103-9.
16. Bittard H, Lamy B, Billery C. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. J Urol 1996;155:1887-91.
17. Baak JPA, Bol MGW, van Diermen B, et al. Comparison of the prognostic value of DNA histogram features assessed by flow and image cytometry in tat1 urothelial cell carcinomas of the urinary bladder. Urology [In press.]
18. UICC. TNM Classification of malignant tumours. Berlin: Springer 1992.
19. Mostofi FK, Davis CJ, Sesterhenn IA. WHO histologic typing of urinary bladder tumors. Berlin: Springer, 1999.
20. Dalesio O, Schulman CC, Sylvester R, et al. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: genitourinary tract cancer cooperative group. Urology 1983;29:730-3.
21. Smits G, Schaafsma E, Kiemeney L, et al. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 1998;52:1009-13.
22. Bol MGW, Baak JPA, Rep S, et al. Improved objectivity of grading of Ta T1 transitional cell carcinomas of the urinary bladder by quantitative nuclear and proliferation related features. J Clin Pathol 2001;54:854-9.
23. Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52.
24. Bohm J, Koch S, Gais P, et al. Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J Pathol 1996;178:402-9.
25. Gontero P, Casetta G, Zitella A, et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000;38:287-96.
26. Baak JPA. Morphometric and combined morphometric-DNA cytometric applications. In: Manual of quantitative pathology in cancer diagnosis and prognosis. Berlin: Springer Verlag, 1991:269-449.
27. Nocito A, Bubendorf L, Maria Tinner E, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-57.
28. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:211-15.
29. Lipponen PK, Eskelinen MJ. Volume-corrected mitotic index and mitotic activity index in transitional cell bladder cancer. Eur Urol 1991;18:258-62.
30. Lipponen PK, Collan Y, Eskelinen MJ, et al. Comparison of morphometry and DNA flow cytometry with standard prognastic factors in bladder cancer. Br J Urol 1990;65:589-97.
31. McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, bladder tumor marker network. Clin Cancer Res 2000;6:1854-64.
32. Baak JPA. Editorial (Perspectives). The framewark of pathology: good laboratory practice by quantitative and molecular methods. J Pathol 2002;198:277-83.